Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 7/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496563 | 1.00 | MEN1 (0.47) | MEN1KMT2APDE4AMAPK1PDE4B | |
| SCHEMBL411529 | 0.82 | POLB (0.49) | MEN1KMT2APOLB | |
| SCHEMBL15508246 | 0.78 | MEN1 (0.59) | MEN1KMT2ATACR2POLB | |
| SCHEMBL16928440 | 0.78 | MEN1 (0.59) | MEN1KMT2ATACR2POLB | |
| SCHEMBL1598073 | 0.78 | MEN1 (0.47) | MEN1KMT2APOLB | |
| SCHEMBL29721614 | 0.76 | KDM4E (0.42) | MEN1KMT2APDE4AMAPK1PDE4B | |
| SCHEMBL682465 | 0.75 | HDAC8 (0.45) | MEN1KMT2ATACR2POLB | |
| SCHEMBL2088808 | 0.75 | HDAC8 (0.45) | MEN1KMT2ATACR2POLB | |
| SCHEMBL682821 | 0.75 | HDAC8 (0.45) | MEN1KMT2ATACR2POLB | |
| SCHEMBL7385157 | 0.75 | HDAC8 (0.47) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140155396-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130252940-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070197795-A1 | METHOD OF MAKING IMIDAZOLE-2-ONES AND 2-THIONES | ALLERGAN, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070117978-A1 | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | ARTESIAN THERAPECUTICS, INC (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070066619-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | ARTESIAN THERAPEUTICS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2007025271-A1 | METHOD OF MAKING IMIDAZOLE-2-ONES AND 2-THIONES | ALLERGAN, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-3979380-A | INOTROPIC ACTIVITY, CARDIAC STIMULANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MEN1 1228/4885KMT2A 977/4885PDE4A 533/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | MEN1 1228/4885KMT2A 977/4885PDE4A 533/4885 |
| US-20140155378-A9 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | MEN1 1333/4885KMT2A 769/4885PDE4A 665/4885 |
| US-20140155396-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | MEN1 1333/4885KMT2A 769/4885PDE4A 665/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MEN1 1228/4885KMT2A 977/4885PDE4A 533/4885 |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ADRB3, PDE3A, PDE3B | MEN1 798/4885KMT2A 2928/4885PDE4A 7/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MEN1 1228/4885KMT2A 977/4885PDE4A 533/4885 |
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ADRB3, PDE3A, PDE3B | MEN1 798/4885KMT2A 2928/4885PDE4A 7/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | MEN1 1228/4885KMT2A 977/4885PDE4A 533/4885 |
| US-20070066619-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | CACNA1C, PDE3A, PDE3B | MEN1 1325/4885KMT2A 3592/4885PDE4A 17/4885 |
| US-20070197795-A1 | METHOD OF MAKING IMIDAZOLE-2-ONES AND 2-THIONES | TPMT, TST, CPS1 | MEN1 1011/4885KMT2A 901/4885PDE4A 3778/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MEN1 1333/4885KMT2A 769/4885PDE4A 665/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | MEN1 1333/4885KMT2A 769/4885PDE4A 665/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MEN1 1333/4885KMT2A 769/4885PDE4A 665/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | MEN1 1228/4885KMT2A 977/4885PDE4A 533/4885 |
| US-20070117978-A1 | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | PDE3A, PDE4A, PDE3B | MEN1 1556/4885KMT2A 4662/4885PDE4A 2/4885 |
| US-20130252940-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | MEN1 1333/4885KMT2A 769/4885PDE4A 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.